AU2013243388B2 - Methods and compositions for increasing red blood cells - Google Patents

Methods and compositions for increasing red blood cells Download PDF

Info

Publication number
AU2013243388B2
AU2013243388B2 AU2013243388A AU2013243388A AU2013243388B2 AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2 AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2
Authority
AU
Australia
Prior art keywords
polypeptide
bmp9
bmp
www
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013243388A
Other languages
English (en)
Other versions
AU2013243388A1 (en
Inventor
John Knopf
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2013243388A1 publication Critical patent/AU2013243388A1/en
Application granted granted Critical
Publication of AU2013243388B2 publication Critical patent/AU2013243388B2/en
Priority to AU2018202326A priority Critical patent/AU2018202326B2/en
Priority to AU2021201196A priority patent/AU2021201196A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013243388A 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells Ceased AU2013243388B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018202326A AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202326A Division AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells

Publications (2)

Publication Number Publication Date
AU2013243388A1 AU2013243388A1 (en) 2014-10-23
AU2013243388B2 true AU2013243388B2 (en) 2018-01-25

Family

ID=49301055

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013243388A Ceased AU2013243388B2 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Country Status (6)

Country Link
US (4) US9809636B2 (enExample)
EP (2) EP2844272A4 (enExample)
JP (4) JP6234993B2 (enExample)
AU (3) AU2013243388B2 (enExample)
CA (1) CA2869474C (enExample)
WO (1) WO2013152213A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
EP3303387A2 (en) 2015-06-05 2018-04-11 Novartis AG Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
SI3496739T1 (sl) 2016-07-15 2021-06-30 Acceleron Pharma Inc. Sestave, ki zajemajo polipeptide actriia, za uporabo pri zdravljenju pljučne hipertenzije
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100255415B1 (ko) 1991-06-25 2000-05-01 브루스 엠. 에이센 비엠피-9 조성물
EP0687272B1 (en) * 1993-03-04 2007-01-17 Stryker Corporation Method and compositions for recombinant osteogenic protein production
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US7741284B2 (en) 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
WO2006105359A2 (en) 2005-03-30 2006-10-05 Wyeth Methods for stimulating hair growth by administering bmps
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
UA116871C2 (uk) * 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
EP2599495A1 (en) 2007-02-01 2013-06-05 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
KR20110031908A (ko) 2008-05-02 2011-03-29 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
CA2724525A1 (en) 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
EP2318028B1 (en) 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2844123T3 (es) 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2874117C (en) * 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
AU2016261913B2 (en) 2015-05-13 2021-08-12 Acceleron Pharma Inc. Treatment of beta-thalassemia using ActRII ligand traps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Also Published As

Publication number Publication date
EP2844272A4 (en) 2015-11-04
JP2021107453A (ja) 2021-07-29
CA2869474C (en) 2021-08-03
JP2019156858A (ja) 2019-09-19
CA2869474A1 (en) 2013-10-10
JP6234993B2 (ja) 2017-11-22
US11807673B2 (en) 2023-11-07
WO2013152213A1 (en) 2013-10-10
US20210277082A1 (en) 2021-09-09
US20180186851A1 (en) 2018-07-05
US20200115428A1 (en) 2020-04-16
JP2017190344A (ja) 2017-10-19
AU2013243388A1 (en) 2014-10-23
AU2018202326B2 (en) 2020-11-26
EP3351260A1 (en) 2018-07-25
JP2015514115A (ja) 2015-05-18
EP3351260B1 (en) 2022-07-13
AU2018202326A1 (en) 2018-04-26
US9809636B2 (en) 2017-11-07
US10344066B2 (en) 2019-07-09
EP2844272A1 (en) 2015-03-11
US20130281371A1 (en) 2013-10-24
AU2021201196A1 (en) 2021-03-11
US10829534B2 (en) 2020-11-10

Similar Documents

Publication Publication Date Title
US11807673B2 (en) Methods and compositions for increasing red blood cells
JP6968917B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP6860533B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP2020186277A (ja) 無効赤血球生成を処置するための方法および組成物
CA2964808C (en) Methods and compositions using gdf15 polypeptides for increasing red blood cells
US20230234998A1 (en) Twisted gastrulation polypeptides and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KUMAR, RAVINDRA; SURAGANI, NAGA VENKATA SAI RAJASEKHAR AND KNOPF, JOHN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired